RxDoctor Payments Data

Sandra Haupt, NP

Family · Monroe, GANPI 1689901639

Payments from drug & device makers

$1,131in general payments, 2019–2025

Across 62 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$409
  • AbbVie$190
  • Dexcom, Inc.$76
  • Bayer$70
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$63
  • Lilly USA, LLC$50
  • plus $274 from 10 others

What the payments were for

  • Food & beverage$1,131100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,131 in reported general payments places this provider in the 70th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$58,344
Medicare patients
122
Services billed
999

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide110$152,299
MounjaroTirzepatide48$86,358
RybelsusSemaglutide14$29,380
Tresiba Flextouch U-100Insulin Degludec22$19,450
EliquisApixaban20$14,773
LinzessLinaclotide12$8,211
Fluticasone-SalmeterolFluticasone Propion/Salmeterol40$8,159
XareltoRivaroxaban13$7,781
Wixela InhubFluticasone Propion/Salmeterol18$3,321
ShingrixVaricella-Zoster Ge/As01b/Pf15$3,084
Buspirone Hcl106$3,084
Albuterol Sulfate HfaAlbuterol Sulfate106$2,841
Atorvastatin Calcium322$2,527
Novolog FlexpenInsulin Aspart11$2,401
Ezetimibe41$2,330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$409$181,679124 claims
Lilly USA, LLCMounjaro$50$86,35848 claims
PfizerEliquis$39$14,77320 claims
AbbVieLinzess, Synthroid$190$9,42926 claims
GSKShingrix$26$3,08415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,258 family providers in Georgia.

Other family in Monroe

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →